Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy

19 Jan 2026 CW Team

The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio.

The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary.

This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026.

The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets.

Net proceeds will be utilised towards:

Payment to Viatris for acquisition of Biocon Biologics shares

Repayment of debt linked to the acquisition

Funding for redemption of compulsorily convertible debentures held by Biocon Biologics

General corporate purposes

The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025.

Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4.15 billion (approximately USD 460 million) through the issuance of 12,664,585 equity shares at an issue price of Rs 368.35 per share, including a premium of Rs 363.35. The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio. The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary. This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026. The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets. Net proceeds will be utilised towards: Payment to Viatris for acquisition of Biocon Biologics shares Repayment of debt linked to the acquisition Funding for redemption of compulsorily convertible debentures held by Biocon Biologics General corporate purposes The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025. Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Infrastructure Urban

06 Apr 2026

CFI Appoints New National Council for FY27 and FY28

The Construction Federation of India (CFI) has announced its newly elected National Council and office bearers for a two-year term covering FY27 and FY28. M. V. Satish, Advisor to CMD and Lead Ambassador for Middle East, L&T, has been elected President; Priti Patel, Chief Strategy & Growth Officer, Tata Projects, has been appointed Vice President; and Ajit Bhate, Managing Director, Precast India Infrastructures, has taken charge as Treasurer.The newly formed National Council brings together senior leaders from major EPC and infrastructure companies, reflecting CFI’s continued focus o..

Infrastructure Urban

06 Apr 2026

India REIT Market Gains Momentum with Strong Returns

India’s Real Estate Investment Trust (REIT) market is witnessing strong growth, emerging as a competitive investment avenue both domestically and across Asia. According to a recent ANAROCK report released at EXCELERATE 2026 by NAREDCO Maharashtra NextGen, the sector is evolving into a mature asset class driven by solid fundamentals, regulatory backing and rising investor confidence.The introduction of Small and Medium REITs (SM REITs) in 2025 has further widened access through fractional ownership, unlocking a potential monetisation opportunity of Rs 670–710 billion. Indian REITs have deli..

Infrastructure Energy

06 Apr 2026

G R Infraprojects Secures Rs 4,130 Million BESS Contract From NTPC

G R Infraprojects said it has secured a contract from NTPC to supply and implement a battery energy storage system (BESS) valued at Rs 4,130 million (mn). The company reported the order was awarded as part of NTPC's ongoing efforts to enhance grid flexibility and energy storage capacity. The contract represents a notable addition to the firm's project pipeline and underscores demand for utility scale storage solutions. The award is expected to strengthen G R Infraprojects' presence in the energy infrastructure sector and to contribute to the firm's order book and future revenues, subject to st..